Home » Newsletters » BioWorld Science

BioWorld Science

April 27, 2006

View Archived Issues

ALS Association awards research funding to Sirtris

Safetek signs term sheet with Resdevco

Dynavax Technologies completes acquisition of Rhein Biotech GmbH

Apaziquone highly active in superficial bladder cancer

Teverelix shows promise in phase II prostate cancer study

Tolterodine improves overactive bladder symptoms and patient quality of life

SUNRISE study reveals urinary urgency improvement with solifenacin

hMaxi-K gene transfer for erectile dysfunction safe in phase I study

Dose proportionality confirmed with BEMA Fentanyl

Antinociceptive activity of neurotoxin receptor site 2-targeting sodium channel blocker

Disappointing results from phase III trial of bicifadine in chronic low back pain

IND approval for Aurora kinase inhibitor AT-9283

Phase II picoplatin study expanded into Eastern Europe

Panzem NCD with paclitaxel studied for metastatic breast cancer

DOD grant supports study of bavituximab in breast cancer

Enrollment completed in study of Chondrogen to repair tissue in the knee

PhytoMedical to focus on development of specific polyphenols

Series B financing at Protez to support development of PZ-601

Target enrollment completed in phase IIa study of E1-I.N.T. for type 2 diabetes

New Asian study for Iressa in first-line NSCLC

Lixivaptan demonstrates aquaretic effects in heart failure patients

ZT-1 evaluated in vivo, in healthy subjects and in Alzheimer's disease patients

European approval and recommendation for new Keppra indications

European approval for Preotact

Vaprisol launched for treatment of euvolemic hyponatremia

Roche seeks European approval for novel anemia drug CERA

Coagulation factor Xa inhibitors prepared and tested at Merck

Recent Bayer patent imparts novel agents for lipoprotein-related disorders

Two recent Pfizer patents describe new histamine H3 receptor antagonists

Newly formed Abraxis Bioscience presents data on nab tumor targeting technology

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...